title: Successful treatment of recurrent focal segmental glomerulosclerosis combined with calcineurin inhibitor nephrotoxicity four yr after kidney transplantation.
abstract: A 31-yr-old Japanese man with end-stage kidney disease caused by primary focal segmental glomerulosclerosis (FSGS) underwent living related kidney transplantation at the age of 26 yr. The allograft functioned well immediately after surgery, and we did not observe histological findings of rejection and recurrent FSGS in protocol biopsies at two months and one yr after transplantation. Four years after transplantation, the urine protein excretion reached 11 g/d, and the serum creatinine increased over 2.5 mg/dL. We diagnosed nephrotic syndrome due to recurrent FSGS with graft dysfunction and confirmed FSGS lesions with severe endothelial injury with an allograft biopsy, associated with calcineurin inhibitor (CNI) nephrotoxicity. Thereafter, we performed plasmapheresis and steroid therapy with subsequent low-density lipoprotein adsorption, combined with the reduction of tacrolimus. The nephrotic syndrome improved dramatically with the multiple therapeutic approaches. Primary FSGS recurs frequently in patients immediately after kidney transplantation. Post-transplant FSGS has various causes, such as recurrent primary disease, obesity, hyperfiltration, donor-related nephrosclerosis, and CNI-induced arteriolopathy. In the case of nephrotic syndrome after kidney transplantation, we should consider not only recurrent FSGS, but also CNI-induced nephrotoxicity to determine the optimal treatment.
authors.affiliation: Division of Kidney and Hypertension, Department of Internal Medicine, The Jikei University School of Medicine, Tokyo, Japan. mitome@jikei.ac.jp
authors.forename: Jun
authors.initials: J
authors.lastname: Mitome
authors.forename: Hiroyasu
authors.initials: H
authors.lastname: Yamamoto
authors.forename: Yukio
authors.initials: Y
authors.lastname: Maruyama
authors.forename: Akimitsu
authors.initials: A
authors.lastname: Kobayashi
authors.forename: Tatsuhiro
authors.initials: T
authors.lastname: Yaginuma
authors.forename: Nanae
authors.initials: N
authors.lastname: Matsuo
authors.forename: Yudo
authors.initials: Y
authors.lastname: Tanno
authors.forename: Hiroshi
authors.initials: H
authors.lastname: Hayakawa
authors.forename: Youichi
authors.initials: Y
authors.lastname: Miyazaki
authors.forename: Keitaro
authors.initials: K
authors.lastname: Yokoyama
authors.forename: Yasunori
authors.initials: Y
authors.lastname: Utsunomiya
authors.forename: Yutaka
authors.initials: Y
authors.lastname: Yamaguchi
authors.forename: Tatsuo
authors.initials: T
authors.lastname: Hosoya
mesh_terms: D000328:Adult; D065095:Calcineurin Inhibitors; D003131:Combined Modality Therapy; D003404:Creatinine / Q000097:blood; D004359:Drug Therapy, Combination; D005923:Glomerulosclerosis, Focal Segmental / Q000150:complications / Q000188:drug therapy*; D006084:Graft Rejection / Q000188:drug therapy*; D006085:Graft Survival; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D016030:Kidney Transplantation; D008297:Male; D009404:Nephrotic Syndrome / Q000139:chemically induced / Q000188:drug therapy*; D012008:Recurrence; D016896:Treatment Outcome
chemical_list: D065095:Calcineurin Inhibitors; D007166:Immunosuppressive Agents; D003404:Creatinine